The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, Alterini R, Rigacci L, Romagnani S, Maggi E

Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab.

International archives of allergy and immunology 2012;159;321-6 — 2012 — 321-6

Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S

Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma.

International journal of hematology 2004 Aug;80;164-7 — 2004 Aug — 164-7

Savage DG, Cohen NS, Hesdorffer CS, Heitjan D, Oster MW, Garrett TJ, Bar M, del Prete S, March R, Lonberg M, Talbot S, Mears JG, Flamm M, Taub RN, Nichols G

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.

Leukemia & lymphoma 2003 Mar;44;477-81 — 2003 Mar — 477-81